| Not Yet Recruiting | A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Thi Advanced Gastric Cancer | N/A | 2026-01-08 |
| Recruiting | Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment Aortic Regurgitation Disease, Aortic Stenosis Disease, Healthy Subjects | — | 2025-12-26 |
| Not Yet Recruiting | An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuva Breast Cancer | Phase 2 | 2025-12-20 |
| Recruiting | QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | 2025-10-30 |
| Not Yet Recruiting | A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatme Breast Cancer | Phase 2 | 2025-10-10 |
| Recruiting | To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer Non-Small Cell Lung Cancer | N/A | 2025-09-20 |
| Not Yet Recruiting | SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression Breast Cancer | Phase 2 | 2025-08-01 |
| Active Not Recruiting | An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Ovary Cancer | Phase 1 / Phase 2 | 2025-07-07 |
| Not Yet Recruiting | Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junc AFP Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After NSCLC (Advanced Non-small Cell Lung Cancer), Resistance to Immunotherapy | Phase 2 | 2025-06-01 |
| Not Yet Recruiting | Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis Colorectal Cancer Metastatic | Phase 2 | 2025-05-01 |
| Active Not Recruiting | METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer Ovarian Cancer | Phase 1 / Phase 2 | 2025-03-13 |
| Recruiting | Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | 2025-02-25 |
| Recruiting | Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy | Phase 2 | 2024-11-20 |
| Recruiting | An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian C Ovarian Cancer | Phase 2 | 2024-06-30 |
| Recruiting | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Main Ovarian Cancer | Phase 2 | 2024-05-25 |
| Recruiting | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epitheli Ovarian Cancer | Phase 1 / Phase 2 | 2024-05-01 |
| Unknown | A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer Non-small Cell Lung Cancer Stage III | Phase 2 | 2022-06-01 |
| Completed | Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors Thrombocytopenia | N/A | 2020-05-26 |